和美药业递表港交所

Core Insights - He Mei Pharmaceutical Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with Guotou Securities International as the sole sponsor [1] - The company, established in 2002, focuses on discovering and developing proprietary small molecule drugs for autoimmune diseases and tumors [1] - The product pipeline includes seven small molecule candidates, with two core products, Mufemilast and Hemay022, and Mufemilast has received NDA approval in China [1] Company Capabilities - He Mei Pharmaceutical has established a comprehensive technical system covering the entire process of small molecule drug development, from early research to industrialization [4] - The system includes a modular compound library construction platform focused on various pharmacological targets, an animal model screening platform driven by pathogen-related biomarkers for efficient candidate drug evaluation, a tumor microenvironment-activated combination chemotherapy drug design platform, and a differentiated clinical design platform to support effective clinical trials [4] - These capabilities enable the company to continuously advance its product pipeline and bring therapies to market to meet medical needs in China and other regions [4]